Keeling I M, Obermayr R P, Schneider B, Spieckermann P G
Department of Surgery, University Hospital, Graz, Austria.
Langenbecks Arch Surg. 2000 Dec;385(8):531-7. doi: 10.1007/s004230000168.
This study assessed the cardioprotective effects of inhibitors of adenosine metabolism in an isolated perfused rat heart model. Specifically, we studied the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)-adenine and the selective nucleoside transport inhibitor S-(p-nitrobenzyl)-6-thioinosine, in terms of their potential to enhance protection when added to Bretschneider's cardioplegic solution.
Rat hearts were infused for 5 min with Krebs-Henseleit buffer solution (group 1), Bretschneider's cardioplegic solution (group 2), Bretschneider's cardioplegic solution with the addition of 25 microM erythro-9-(2-hydroxy-3-nonyl)-adenine and 5 microM S-(p-nitrobenzyl)-6-thioinosine (group 3), and Bretschneider's cardioplegic solution with the addtion of 25 microM erythro-9-(2-hydroxy-3-nonyl)-adenine only (group 4). After cardioplegic arrest and 45 min of ischemic storage at 25 degrees C, the functional recovery of the hearts was tested during 15 min of Langendorff reperfusion and then 45 min of working heart reperfusion.
In relation to the cardioprotective effects of Bretschneider's cardioplegic solution alone, we observed an improved recovery of hemodynamic function of the hearts with the addition of both erythro-9-(2-hydroxy-3-nonyl)-adenine and S-(p-nitrobenzyl)-6-thioinosine. However, the myocardial adenosine triphosphate (ATP) concentration remained unchanged. Bradycardia observed under the addition of erythro-9-(2-hydroxy-3-nonyl)-adenine alone was prevented by the addition of S-(p-nitrobenzyl)-6-thioinosine.
A combination of both substances may be tested further for cardiac preservation, as it might improve the recovery from ischemia at moderate temperatures.
本研究在离体灌注大鼠心脏模型中评估了腺苷代谢抑制剂的心脏保护作用。具体而言,我们研究了腺苷脱氨酶抑制剂赤藓红-9-(2-羟基-3-壬基)-腺嘌呤和选择性核苷转运抑制剂S-(对硝基苄基)-6-硫代肌苷,考察它们添加到布雷施奈德心脏停搏液中增强保护作用的潜力。
用 Krebs-Henseleit 缓冲溶液灌注大鼠心脏 5 分钟(第 1 组),用布雷施奈德心脏停搏液灌注(第 2 组),用添加了 25 μM 赤藓红-9-(2-羟基-3-壬基)-腺嘌呤和 5 μM S-(对硝基苄基)-6-硫代肌苷的布雷施奈德心脏停搏液灌注(第 3 组),以及用仅添加了 25 μM 赤藓红-9-(2-羟基-3-壬基)-腺嘌呤的布雷施奈德心脏停搏液灌注(第 4 组)。在心脏停搏并于 25℃缺血保存 45 分钟后,在 Langendorff 再灌注 15 分钟然后工作心脏再灌注 45 分钟期间测试心脏的功能恢复情况。
与单独使用布雷施奈德心脏停搏液的心脏保护作用相比,我们观察到添加赤藓红-9-(2-羟基-3-壬基)-腺嘌呤和 S-(对硝基苄基)-6-硫代肌苷后心脏的血流动力学功能恢复得到改善。然而,心肌三磷酸腺苷(ATP)浓度保持不变。单独添加赤藓红-9-(2-羟基-3-壬基)-腺嘌呤时观察到的心动过缓通过添加 S-(对硝基苄基)-6-硫代肌苷得以预防。
这两种物质的组合可能值得进一步测试其心脏保存效果,因为它可能改善中等温度下缺血后的恢复情况。